Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...

Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...

The decision to expand the trial was made following the completion of monotherapy dose escalation for SON-1010.

Where to read this sonnet: Poetry Foundation. 1. Sonnet 18: “Shall I compare thee to a summer’s day?” (1609) Sonnet 18, arguably the most iconic of all Shakespeare’s sonnets, claims the ...

(the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today an expansion of its Phase 1 SB101 clinical study of SON-1010 (IL12-F H AB ...

Sonnets are a form of poem that was much loved by William Shakespeare. This one might be his most famous: Sonnet 18. 'Shall I compare thee to a summer’s day?' asks Shakespeare. A sonnet is ...

Sonnet has a new Thunderbolt 5 dock with four TB5 ports and an internal PCIe 4.0 NVMe SSD slot that'll work with your existing M-series Macs and ensure future compatibility with higher speeds ...